ADD/ADHD News

The FDA today approved the first generic of Strattera for treatment of ADHD in children and adults.

SAN DIEGO — In this video, Norman Atkins, Jr., MBA, PhD, global medical lead for ADHD at Shire Medical Affairs, outlines new poster data that advances the understanding of ADHD in adults.

Low-income children with chronic conditions and their families could experience drastic cost increases for health care — as much as $233 to $2,472 in annual expenditures, depending on income levels and individual needs — if the Children’s Health Insurance Program is not renewed and the families are switched to Marketplace health insurance plans.

Individuals with ADHD were significantly less likely to experience motor vehicle crashes when receiving medication for the disorder.

Youth who screened positive for ADHD, conduct problems, violence and aggression were more likely to report increased access to firearms, according to data presented at the Pediatric Academic Societies Meeting.

Children who experienced racial discrimination were more likely to exhibit anxiety and depression, as well as an increased risk for attention deficit/hyperactivity disorder, according to research presented at the 2017 Pediatric Academic Societies Meeting.

Aevi Genomic Medicine recently presented updated responder data from the SAGA trial of AEVI-001, an oral nonstimulant, for adolescent ADHD.

Recent findings indicated dasotraline, a dopamine and norepinephrine reuptake inhibitor, significantly improved ADHD outcomes in the classroom among children aged 6 to 12 years.

Shire recently announced that Vyvanse is now available in the U.S. as a chewable tablet.

A recent study indicated accuracy of a version of the WHO Adult ADHD Self-Report Scale updated to include DSM-5 criteria for adult ADHD.